MedPath

Progesterone

Generic Name
Progesterone
Brand Names
Bijuva, Crinone, Endometrin, Prochieve, Prometrium
Drug Type
Small Molecule
Chemical Formula
C21H30O2
CAS Number
57-83-0
Unique Ingredient Identifier
4G7DS2Q64Y
Background

Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss . Progesterone is used in various contraceptive preparations to prevent ovulation and fertilization , as well as in other formulations to promote and support pregnancy. Please see Medroxyprogesterone acetate, Megestrol acetate, Dydrogesterone and Hydroxyprogesterone entries for information on various other forms of progesterone.

Pharmaceutical progesterone is made from a plant source as a starting material and is chemically identical to progesterone of human ovarian origin . Progesterone is available in gelatinized capsule form, vaginal gel form, tablet form, vaginal insert form, and injection form, all used for various purposes .

Indication

Gelatinized capsules

The gelatinized capsules are indicated for use in the prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea .

Vaginal gel

Progesterone gel (8%) is indicated as progesterone supplementation or replacement as part of an Assisted Reproductive Technology (“ART”) treatment for infertile women with progesterone deficiency. The lower concentration progesterone gel (4%) is used in the treatment of secondary amenorrhea, with the use of the 8% concentration if there is no therapeutic response to the 4% gel .

Vaginal insert

This form is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women .

Injection (intramuscular)

This drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer .

Tablets, contraceptive

The tablet form of progesterone in contraceptive formulations is indicated for the prevention of pregnancy .

Associated Conditions
Abnormal Uterine Bleeding, Amenorrhea, Endometrial hyperplasia caused by conjugated estrogen, Moderate to Severe Vasomotor Symptoms, Pregnancy, Secondary Amenorrhea, Recurrent spontaneous preterm birth
Associated Therapies
Assisted Reproductive Technology therapy

Estrogen Variability and Irritability During the Menopause Transition

Phase 4
Recruiting
Conditions
Menopause
Irritable Mood
Interventions
First Posted Date
2022-05-24
Last Posted Date
2023-10-04
Lead Sponsor
University of North Carolina, Chapel Hill
Target Recruit Count
50
Registration Number
NCT05388656
Locations
🇺🇸

Carolina Crossing B, Suite 1, Chapel Hill, North Carolina, United States

HOPE Trial hCG or Progesterone Effect on Recurrent Pregnancy Loss

Phase 2
Withdrawn
Conditions
Recurrent Pregnancy Loss Without Current Pregnancy
Interventions
First Posted Date
2022-05-09
Last Posted Date
2022-05-09
Lead Sponsor
Wake Forest University Health Sciences
Registration Number
NCT05365464

Clinical and Basic Researches Related to ZhenQi Buxue Oral Liquid in Treating Menstrual Disorders

Not Applicable
Conditions
Menstrual Disorders
Interventions
Drug: ZhenQi BuXue KouFuYe
First Posted Date
2022-04-05
Last Posted Date
2022-04-05
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
330
Registration Number
NCT05312190
Locations
🇨🇳

Lei Li, Beijing, Beijing, China

🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support

Phase 4
Completed
Conditions
Female Infertility
Interventions
Drug: gonadotropin releasing hormone-agonist
First Posted Date
2022-03-18
Last Posted Date
2025-01-29
Lead Sponsor
Alexandria University
Target Recruit Count
75
Registration Number
NCT05286554
Locations
🇪🇬

Alexandria University, Alexandria, Egypt

Examining the Effects of Estradiol on Neural and Molecular Response to Reward

Phase 4
Recruiting
Conditions
Psychosis
Anhedonia
Depression
Interventions
First Posted Date
2022-03-16
Last Posted Date
2025-02-26
Lead Sponsor
University of North Carolina, Chapel Hill
Target Recruit Count
103
Registration Number
NCT05282277
Locations
🇺🇸

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Comparison of the Effect of Subcutaneous Progesterone and Vaginal Progesterone for Luteal Phase Support

Not Applicable
Completed
Conditions
Progesterone
Interventions
First Posted Date
2022-03-11
Last Posted Date
2022-09-09
Lead Sponsor
Bezmialem Vakif University
Target Recruit Count
146
Registration Number
NCT05276531
Locations
🇹🇷

Bezmialem Vakif University, Istanbul, Turkey

Hormonal Monitoring and Progesterone Adjustment in Frozen Embryo Transfer Cycles

Not Applicable
Completed
Conditions
Female Infertility
Interventions
Diagnostic Test: transvaginal ultrasound examination
Other: Hormonal monitoring progesterone, estradiol, luteinizing hormone
Other: Hormonal monitoring progesterone and estradiol
First Posted Date
2022-01-12
Last Posted Date
2024-02-02
Lead Sponsor
Alexandria University
Target Recruit Count
600
Registration Number
NCT05189145
Locations
🇪🇬

Infertility Center, Alexandria, Egypt

PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)

Early Phase 1
Recruiting
Conditions
Postpartum Abstinence
Methamphetamine-dependence
Interventions
Drug: Placebo
First Posted Date
2021-11-19
Last Posted Date
2024-05-21
Lead Sponsor
University of Utah
Target Recruit Count
40
Registration Number
NCT05128071
Locations
🇺🇸

University of Utah, Salt Lake City, Utah, United States

Fasting Bioequivalence Study of 2 Progesterone Soft Capsules 200 mg in 66 Healthy Female Subjects Under Vaginal Route

Phase 1
Completed
Conditions
Pharmacokinetics
Interventions
First Posted Date
2021-11-18
Last Posted Date
2021-11-18
Lead Sponsor
Joint Stock Company "Farmak"
Target Recruit Count
66
Registration Number
NCT05125627
Locations
🇯🇴

Arab Pharmaceutical Industry Consulting/Pharmaceutical Research Unit, Amman, Jordan

Fasting Bioequivalence Study of 2 Oral Progesterone Soft Capsules 200 mg in 48 Healthy Female Subjects

Phase 1
Completed
Conditions
Pharmacokinetics
Interventions
First Posted Date
2021-11-18
Last Posted Date
2021-11-18
Lead Sponsor
Joint Stock Company "Farmak"
Target Recruit Count
48
Registration Number
NCT05125640
Locations
🇯🇴

Arab Pharmaceutical Industry Consulting/Pharmaceutical Research Unit, Amman, Jordan

© Copyright 2025. All Rights Reserved by MedPath